Management of patients with persistent and recurrent acromegaly-Reference-Cited by-同舟云学术

Management of patients with persistent and recurrent acromegaly

Published:2021-03-28 Issue:4 Volume: Page:265-270
ISSN:2074-6822
Container-title:Vestnik nevrologii, psihiatrii i nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
language:ru
Short-container-title:

Author:

Ibrahim Sameh Ragab Awad¹,Shkarubo Aleksey Nikolaevich²^ORCID,Astafieva Lyudmila Igorevna³^ORCID,Chmutin Gennadiy Egorovich⁴,Chmutin Egor Gennadievich⁴^ORCID

Affiliation:

1. Peoples’ Friendship University of Russia (RUDN University), Moscow, Russia

2. FSAI N. N. Burdenko National Medical Research Center for Neurosurgery of the Ministry of Health of Russia, Medical Institute, Peoples’ Friendship University of Russia

3. FSAI N. N. Burdenko National Medical Research Center for Neurosurgery, Medical Institute, Peoples’ Friendship University of Russia

4. Medical Institute, Peoples’ Friendship University of Russia

Abstract

Acromegaly is a multisystem chronic disease characterized by hypersecretion of growth hormone. Effective treatment of acromegaly is extremely necessary, as this pathology is often associated with comorbid conditions (diabetes mellitus, arterial hypertension, sleep apnea syndrome, cardiac hypertrophy) and rare complete clinical and laboratory remission. This article describes treatment options for persistent and recurrent acromegaly that include surgery, pharmacological therapy and radiation therapy.

Publisher

PANORAMA Publishing House

Reference21 articles.

1. Van Der Lely A. J., RJ M. A. J. J. A. D. Zib KA Scarlett JA & Lamberts SW. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient // Journal of Clinical Endocrinology and Metabolism. 2001; 86: 478–481.

2. Belaya Zh. E. et al. Epidemiology, clinical manifestations and effectiveness of various methods of treatment of acromegaly according to the data of the unified Russian register of tumors of the hypothalamic-pituitary system / / Problems of Endocrinology. 2020; 66: 1: 93–103.

3. Roelfsema F., Biermasz N. R., Pereira A. M. Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis // Pituitary. 2012; 15: 1: 71–83.

4. Wang Y. Y. et al. Acromegaly surgery in Manchester revisited — the impact of reducing surgeon numbers and the 2010 consensus guidelines for disease remission // Clinical endocrinology. 2012; 76: 3: 399–406.

5. Dusek T. et al. Clinical features and therapeutic outcomes of patients with acromegaly: single-center experience // Journal of endocrinological investigation. 2011; 34: 11: e382 — e385.